Table 1.
Clinical characteristics of the study population.
| Variables | Total (n = 581) |
|---|---|
| Demographic data | - |
| Age, years, median (IQR) | 61 (53-69) |
| Sex (male), n (%) | 423 (72.8) |
| Risk factors | - |
| Current smoking, n (%) | 326 (56.1) |
| Current drinking, n (%) | 253 (43.5) |
| Atrial fibrillation, n (%) | 27 (4.6) |
| Coronary artery disease, n (%) | 116 (20) |
| Diabetes, n (%) | 189 (32.5) |
| Hypertension, n (%) | 302 (52) |
| Time from stroke onset to IVT infusion (min), median (IQR) | 180 (141-230) |
| Prior stroke, n (%) | 88 (15.1) |
| Laboratory tests | - |
| Systolic blood pressure, mmHg, median (IQR) | 154 (138-165) |
| Diastolic blood pressure, mmHg, median (IQR) | 89 (80-98) |
| Baseline blood glucose, mmol/L, median (IQR) | 6.92 (6.13-8.65) |
| Baseline NIHSS score, median (IQR) | 9 (5-13) |
| Baseline neutrophil(109/L), median (IQR) | 5.41 (3.98-7.44) |
| Baseline PLT (109/L), median (IQR) | 200 (170-231) |
| Baseline PNR, median (IQR) | 36.71 (26.04-51.29) |
| Post-IVT neutrophil (109/L), median (IQR) | 5.39 (4.23-7.26) |
| Medications | - |
| Antihypertensive therapy, n (%) | 200 (34.4) |
| Antiplatelet therapy, n (%) | 73 (12.6) |
| Hypoglycemic therapy, n (%) | 102 (17.6) |
| Post-IVT PLT (109/L), median (IQR) | 205 (173-237) |
| Post-IVT PNR, median (IQR) | 37.76 (27.16-49.33) |
| Outcome events | - |
| END, n (%) | 50 (8.6) |
| HT, n (%) | 82 (14.1) |
| DND, n (%) | 25 (4.3) |
| Poor 3-month outcome, n (%) | 190 (32.7) |
Abbreviations: NIHSS, National Institute of Health Stroke Scale; PLT, Platelet; PNR, Platelet-To-Neutrophil Ratio; IVT, intravenous Thrombolysis; END, Early Neurologic Deterioration; HT, Hemorrhagic Transformation; DND, Delayed Neurological Deterioration.